Literature DB >> 15047169

PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency.

Katsuhiko Naoki1, Koichiro Asano, Nagato Satoh, Kouichi Fukunaga, Tsuyoshi Oguma, Tetsuya Shiomi, Yusuke Suzuki, Takeshi Nakajima, Kyoko Niimi, Yoshiki Shiraishi, Akitoshi Ishizaka, Kazuhiro Yamaguchi.   

Abstract

Approximately 4% of the Japanese population genetically lack plasma platelet activating factor acetylhydrolase (PAF-AH) and show a higher prevalence of thromboembolic disease, but whether they are susceptible to another PAF-related disease, asthma, remains controversial. To determine the role of plasma PAF-AH in airway physiology, we performed PAF bronchoprovocation tests in 8 plasma PAF-AH-deficient subjects and 16 control subjects. Serial inhalation of PAF (1-1000 microg/ml) concentration-dependently induced acute bronchoconstriction, but there was no significant difference between PAF-AH-deficient and control subjects (11.7 +/- 4.6% vs. 9.6 +/- 2.8% decrease in forced expiratory volume in 1 s). Transient neutropenia after single inhalation of PAF (1000 microg/ml) showed no significant difference between the groups either in its magnitude (72 +/- 11% vs. 65 +/- 9% decrease) or duration (4.1 +/- 1.0 vs. 3.3 +/- 0.8 min). In conclusion, a lack of plasma PAF-AH activity alone does not augment physiological responses to PAF in the airway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047169     DOI: 10.1016/j.bbrc.2004.03.031

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

Review 2.  Multiple roles of phospholipase A2 during lung infection and inflammation.

Authors:  Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

Review 3.  Platelet activating factor as a mediator and therapeutic approach in bronchial asthma.

Authors:  A Kasperska-Zajac; Z Brzoza; B Rogala
Journal:  Inflammation       Date:  2008-01-12       Impact factor: 4.092

4.  The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice.

Authors:  Zhilong Jiang; Melane L Fehrenbach; Giulia Ravaioli; Blerina Kokalari; Imre G Redai; Steven A Sheardown; Stephen Wilson; Colin Macphee; Angela Haczku
Journal:  Respir Res       Date:  2012-11-12

5.  Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.

Authors:  Bonnie C Shaddinger; Yanmei Xu; James H Roger; Colin H Macphee; Malcolm Handel; Charlotte A Baidoo; Mindy Magee; John J Lepore; Dennis L Sprecher
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.